Neurality raises $76M to develop gut-brain axis drugs for Parkinson's GI symptoms
Summary
Maryland-based Neuraly secured $76M Series B from Pfizer Ventures, AbbVie Ventures, Eli Lilly, and Biogen Ventures for NAL-101, targeting gastrointestinal symptoms in Parkinson's via enteric nervous system modulation. Up to 80% of Parkinson's patients experience debilitating GI symptoms decades before motor signs appear, suggesting enteric nervous system dysfunction is an early disease feature.
Why it matters
Parkinson's GI symptoms are undertreated and may actually represent the disease's earliest manifestation. A drug that works via the enteric nervous system rather than the brain could be safer and more tolerable than current Parkinson's medications, particularly for early intervention.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial